Tuesday, March 29, 2016

Explaining Valeant: The Main Theories by STEVEN DAVIDOFF SOLOMON


By STEVEN DAVIDOFF SOLOMON

Reasons given for the turmoil at Valeant Pharmaceuticals include its cuts in research and development, its drug pricing and investors’ influence.

Published: March 30, 2016 at 12:00AM

from NYT Business Day http://ift.tt/1UTm0uh



from WordPress http://ift.tt/1UTmsZA
via Hadi Aboukhater
Posted by at
Labels: , , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)